Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Characteristics and treatment history of the simulated population of patients with ankylosing spondylitis on January 1, 2014

From: Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study

Attribute

Summary statistics of the 67,145 patients in the Dutch society based on the simulated data

Min

Median

Mean (SD)

Max

Age of male

15.6

43.2

43.8 (12.2)

80.5

Age of female

15.7

43.5

44.2 (12.3)

80.4

Symptom duration (year)

0

25.2

25.1 (10.8)

78.5

Diagnosis duration (year)

0

14.3

15.9 (10.7)

54.8

BASDAI (on 1–10 scale)

0

2.66

2.97 (1.57)

8.96

BASDFI (on 1–10 scale)

0

3.86

3.93 (1.92)

9.81

  1. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us